Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | APG-2575 + Olverembatinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
APG-2575 | APG 2575|APG2575|Lisaftoclax | BCL2 inhibitor 27 | APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (PMID: 32093809, PMID: 37074726). | |
Olverembatinib | HQP 1351|HQP-1351|GZD824 dimesylate|GZD824|HQP1351 | ABL1 Inhibitor 8 FGFR1 Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-alpha Inhibitor 10 | Olverembatinib (HQP1351) is a third-generation BCR-ABL inhibitor and multikinase inhibitor that inhibits KIT, ABL1, FGFR1, FLT3, and PDGFRA (PMID: 32247263), which potentially induces apoptosis, and inhibits tumor cell growth, migration, and invasion (PMID: 31673329). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | APG-2575 + Olverembatinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, combination treatment with Olverembatinib (HQP1351) and APG-2575 induced apoptosis to a greater degree than either therapy alone in acute myeloid leukemia cells harboring FLT3-ITD in culture, and resulted in a synergistic tumor burden reduction in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring FLT3-ITD and inhibited tumor growth in a cell line xenograft model with a T/C ratio of 2.8% (PMID: 34710737). | 34710737 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|